Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial
Richard G Wunderink, Evangelos J Giamarellos-Bourboulis, Galia Rahav, Amy J Mathers, Matteo Bassetti, Jose Vazquez, Oliver A Cornely, Joseph Solomkin, Tanaya Bhowmick, Jihad Bishara, George L Daikos, Tim Felton, Maria Jose Lopez Furst, Eun Jeong Kwak, Francesco Menichetti, Ilana Oren, Elizabeth L Alexander, David Griffith, Olga Lomovskaya, Jeffery Loutit, Shu Zhang, Michael N Dudley, Keith S Kaye, Richard G Wunderink, Evangelos J Giamarellos-Bourboulis, Galia Rahav, Amy J Mathers, Matteo Bassetti, Jose Vazquez, Oliver A Cornely, Joseph Solomkin, Tanaya Bhowmick, Jihad Bishara, George L Daikos, Tim Felton, Maria Jose Lopez Furst, Eun Jeong Kwak, Francesco Menichetti, Ilana Oren, Elizabeth L Alexander, David Griffith, Olga Lomovskaya, Jeffery Loutit, Shu Zhang, Michael N Dudley, Keith S Kaye
Abstract
Introduction: Treatment options for carbapenem-resistant Enterobacteriaceae (CRE) infections are limited and CRE infections remain associated with high clinical failure and mortality rates, particularly in vulnerable patient populations. A Phase 3, multinational, open-label, randomized controlled trial (TANGO II) was conducted from 2014 to 2017 to evaluate the efficacy/safety of meropenem-vaborbactam monotherapy versus best available therapy (BAT) for CRE.
Methods: A total of 77 patients with confirmed/suspected CRE infection (bacteremia, hospital-acquired/ventilator-associated bacterial pneumonia, complicated intra-abdominal infection, complicated urinary tract infection/acute pyelonephritis) were randomized, and 47 with confirmed CRE infection formed the primary analysis population (microbiologic-CRE-modified intent-to-treat, mCRE-MITT). Eligible patients were randomized 2:1 to meropenem-vaborbactam (2 g/2 g over 3 h, q8h for 7-14 days) or BAT (mono/combination therapy with polymyxins, carbapenems, aminoglycosides, tigecycline; or ceftazidime-avibactam alone). Efficacy endpoints included clinical cure, Day-28 all-cause mortality, microbiologic cure, and overall success (clinical cure + microbiologic eradication). Safety endpoints included adverse events (AEs) and laboratory findings.
Results: Within the mCRE-MITT population, cure rates were 65.6% (21/32) and 33.3% (5/15) [95% confidence interval (CI) of difference, 3.3% to 61.3%; P = 0.03)] at End of Treatment and 59.4% (19/32) and 26.7% (4/15) (95% CI of difference, 4.6% to 60.8%; P = 0.02) at Test of Cure;.Day-28 all-cause mortality was 15.6% (5/32) and 33.3% (5/15) (95% CI of difference, - 44.7% to 9.3%) for meropenem-vaborbactam versus BAT, respectively. Treatment-related AEs and renal-related AEs were 24.0% (12/50) and 4.0% (2/50) for meropenem-vaborbactam versus 44.0% (11/25) and 24.0% (6/25) for BAT. Exploratory risk-benefit analyses of composite clinical failure or nephrotoxicity favored meropenem-vaborbactam versus BAT (31.3% [10/32] versus 80.0% [12/15]; 95% CI of difference, - 74.6% to - 22.9%; P < 0.001).
Conclusions: Monotherapy with meropenem-vaborbactam for CRE infection was associated with increased clinical cure, decreased mortality, and reduced nephrotoxicity compared with BAT.
Clinical trials registration: NCT02168946.
Funding: The Medicines Company.
Keywords: Best available therapy; Carbapenem-resistant Enterobacteriaceae; Meropenem–vaborbactam; Randomized clinical trial; TANGO II.
Figures
References
- Bassetti M, Poulakou G, Ruppe E, Bouza E, Van Hal SJ, Brink A. Antimicrobial resistance in the next 30 years, humankind, bugs and drugs: a visionary approach. Intensive Care Med. 2017 doi: 10.1007/s00134-017-4878.
- Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. . Accessed 27 Aug 2017.
- World Health Organization. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. . Accessed 5 Sep 2017.
- European Commission. A European One Health action plan against antimicrobial resistance (AMR). . Accessed 5 Sep 2017.
- The Pew Charitable Trusts. GAIN: how a new law is stimulating the development of antibiotics. . Accessed 5 Sep 2017.
- O’Neill J. Tackling drug-resistant infections globally: an overview of our work. The review on antimicrobial resistance. London: Wellcome Trust; 2016.
- Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008;8(3):159–166. doi: 10.1016/S1473-3099(08)70041-0.
- Munoz-Price LS, Poirel L, Bonomo RA, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis. 2013;13(9):785–796. doi: 10.1016/S1473-3099(13)70190-7.
- Giacobbe DR, Del Bono V, Trecarichi EM, et al; ISGRI-SITA (Italian Study Group on Resistant Infections of the Società Italiana Terapia Antinfettiva). Risk factors for bloodstream infections due to colistin-resistant KPC-producing Klebsiella pneumoniae: results from a multicenter case-control-control study. Clin Microbiol Infect. 2015;21(12):1106.e1–1106.e8.
- Monaco M, Giani T, Raffone M, et al. Colistin resistance superimposed to endemic carbapenem-resistant Klebsiella pneumoniae: a rapidly evolving problem in Italy, November 2013 to April 2014. Euro Surveill. 2014;19(42):14–18. doi: 10.2807/1560-7917.ES2014.19.42.20939.
- Shields RK, Chen L, Cheng S, et al Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother. 2017;61(3):3e02097-16-3e020916.
- Alexander EL, Loutit J, Tumbarello M, et al. Carbapenem-resistant Enterobacteriaceae infections: results from a retrospective series and implications for the design of prospective clinical trials. Open Forum Inf Dis. 2017;4(2):ofx063.
- Falagas ME, Lourida P, Poulikakos P, Rafailidis PI, Tansarli GS. Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence. Antimicrob Agents Chemother. 2014;58(2):654–663. doi: 10.1128/AAC.01222-13.
- Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis. 2012;55(7):943–950. doi: 10.1093/cid/cis588.
- Daikos GL, Tsaousi S, Tzouvelekis LS, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother. 2014;58(4):2322–2328. doi: 10.1128/AAC.02166-13.
- Pouch SM, Satlin MJ. Carbapenem-resistant Enterobacteriaceae in special populations: solid organ transplant recipients, stem cell transplant recipients, and patients with hematologic malignancies. Virulence. 2017;8(4):391–402. doi: 10.1080/21505594.2016.1213472.
- Hecker SJ, Reddy KR, Totrov M, et al. Discovery of a cyclic boronic acid beta-lactamase inhibitor (RPX7009) with utility vs. class A serine carbapenemases. J Med Chem. 2015;58(9):3682–3692. doi: 10.1021/acs.jmedchem.5b00127.
- Rubino CM, Bhavnani SM, Loutit JS, Morgan EE, White D, Dudley MN, Griffith DC. Phase 1 study of the safety, tolerability, and pharmacokinetics of vaborbactam and meropenem alone and in combination following single and multiple doses in healthy adult subjects. Antimicrob Agents Chemother. 2018 doi: 10.1128/AAC.02228-17.
- Kaye KS, Bhowmick T, Metallidis S, et al. Effect of meropenem–vaborbactam vs. piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial. JAMA. 2018;319(8):788–799. doi: 10.1001/jama.2018.0438.
- FDA approves new antibacterial drug [press release]. Silver Spring, MD: US Food and Drug Administration; August 29, 2017. . Accessed 3 Sep 2017.
- Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13(10):818–829. doi: 10.1097/00003246-198510000-00009.
- Clinical and Laboratory Standards Institute . Performance standards for antimicrobial susceptibility testing. Wayne: Clinical and Laboratory Standards Institute; 2014.
- European Committee on Antimicrobial Susceptibility Testing. Antimicrobial susceptibility testing. 2014. . Accessed 27 Aug 2017.
- US Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE). . Accessed 27 Aug 2017.
- Bellomo R, Kellum J, Ronco C. Acute renal failure: time for consensus. Intensive Care Med. 2001;27(11):1685–1688. doi: 10.1007/s00134-001-1120-6.
- Tumbarello M, Trecarichi EM, De Rosa FG, et al. ISGRI-SITA (Italian Study Group on Resistant Infections of the Società Italiana Terapia Antinfettiva). Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother. 2015;70(7):2133–2143. doi: 10.1093/jac/dkv086.
- Daikos GL, Petrikkos P, Psichogiou M, et al. Prospective observational study of the impact of VIM-1 metallo-beta-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections. Antimicrob Agents Chemother. 2009;53(5):1868–1873. doi: 10.1128/AAC.00782-08.
- Cerqueira GC, Earl AM, Ernst CM, et al. Multi-institute analysis of carbapenem resistance reveals remarkable diversity, unexplained mechanisms, and limited clonal outbreaks. Proc Natl Acad Sci USA. 2017;114(5):1135–1140. doi: 10.1073/pnas.1616248114.
- Glasner C, Albiger B, Buist G, et al Carbapenemase-producing Enterobacteriaceae in Europe: a survey among national experts from 39 countries, February 2013. Euro Surveill. 2013;18(28):20525. . Accessed 27 Aug 2017.
- Lewis SJ, Mueller BA. Antibiotic dosing in patients with acute kidney injury: ‘enough but not too much’. J Intensive Care Med. 2014;31(3):164–176. doi: 10.1177/0885066614555490.
Source: PubMed